• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠通透性与肝硬化并发症:一项前瞻性队列研究。

Intestinal permeability and complications in liver cirrhosis: A prospective cohort study.

机构信息

Departments of Gastroenterology and Human Nutrition Microbiology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Hepatol Res. 2013 Feb;43(2):200-7. doi: 10.1111/j.1872-034X.2012.01054.x. Epub 2012 Jun 21.

DOI:10.1111/j.1872-034X.2012.01054.x
PMID:22726344
Abstract

AIM

Increased intestinal permeability (IP) has been implicated as an important factor for bacterial translocation (BT), leading to bacteremia and endotoxemia, resulting in various septic complications, variceal bleeding (VB), hepatic encephalopathy (HE), hepatorenal syndrome (HRS) and death in patients with liver cirrhosis (LC). This study was planned to assess IP in patients with LC and follow them for the occurrence of complications.

METHODS

Patients with Child B and C cirrhosis without a history of disease-related complications were followed up for 6 months. IP was measured by lactulose and mannitol excretion ratio (LMR) in patients and 50 healthy controls (HC). Serum endotoxin levels were also assessed in 48 patients and 20 HC.

RESULTS

Eighty patients (74 male), 41 (51.3%) Child B and 56 (70%) Child C, with a mean age of 40.7 ± 9.8 years were enrolled. IP was increased in 28 (35%) patients. LMR of patients was higher than HC (patients vs HC = 0.0238 [0.0010-1.557] vs 0.0166 [0.0018-0.720]; P = 0.007]. No significant difference was seen in the LMR of patients among various Child classes and etiologies. Serum endotoxin levels (GMU/mL) were higher in patients than HC (patients vs HC = 1.42 [0.68-2.13] vs 0.994 [0.067-1.382]; P = 0.001), but comparable between patients with abnormal and normal IP. At follow up, there was no significant difference in the incidence of complications like spontaneous bacterial peritonitis, HRS, VB, HE and death between patients with abnormal and normal IP.

CONCLUSION

IP was increased in 35% of patients with LC; however, it was not associated with a higher incidence of disease-related complications.

摘要

目的

增加的肠道通透性 (IP) 被认为是细菌易位 (BT) 的一个重要因素,导致菌血症和内毒素血症,从而导致各种脓毒症并发症、静脉曲张出血 (VB)、肝性脑病 (HE)、肝肾综合征 (HRS) 和肝硬化 (LC) 患者死亡。本研究旨在评估 LC 患者的 IP 并观察他们发生并发症的情况。

方法

对无疾病相关并发症病史的 Child B 和 C 级肝硬化患者进行随访 6 个月。通过乳果糖和甘露醇排泄率 (LMR) 测量患者和 50 名健康对照者 (HC) 的 IP。还评估了 48 名患者和 20 名 HC 的血清内毒素水平。

结果

共纳入 80 例患者(74 名男性),其中 41 例(51.3%)为 Child B,56 例(70%)为 Child C,平均年龄为 40.7±9.8 岁。28 例(35%)患者存在 IP 增加。患者的 LMR 高于 HC(患者 vs HC=0.0238[0.0010-1.557]vs 0.0166[0.0018-0.720];P=0.007)。不同 Child 级和病因的患者 LMR 无显著差异。患者的血清内毒素水平(GMU/mL)高于 HC(患者 vs HC=1.42[0.68-2.13]vs 0.994[0.067-1.382];P=0.001),但 IP 异常和正常的患者之间无差异。随访期间,IP 异常和正常的患者自发性细菌性腹膜炎、HRS、VB、HE 和死亡等并发症的发生率无显著差异。

结论

LC 患者中 35%存在 IP 增加,但与疾病相关并发症的发生率增加无关。

相似文献

1
Intestinal permeability and complications in liver cirrhosis: A prospective cohort study.肠通透性与肝硬化并发症:一项前瞻性队列研究。
Hepatol Res. 2013 Feb;43(2):200-7. doi: 10.1111/j.1872-034X.2012.01054.x. Epub 2012 Jun 21.
2
Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study.小肠通透性双糖测试对肝硬化患者细菌感染和死亡率的预测价值不佳:一项前瞻性研究。
World J Gastroenterol. 2016 Mar 21;22(11):3275-84. doi: 10.3748/wjg.v22.i11.3275.
3
NMR-based urinary profiling of lactulose/mannitol ratio used to assess the altered intestinal permeability in acute on chronic liver failure (ACLF) patients.基于核磁共振的乳果糖/甘露醇比率尿液分析用于评估慢性肝衰竭急性加重(ACLF)患者肠道通透性的改变。
Magn Reson Chem. 2017 Apr;55(4):289-296. doi: 10.1002/mrc.4525. Epub 2016 Sep 29.
4
Intestinal permeability in liver cirrhosis: relationship with severe septic complications.
Eur J Gastroenterol Hepatol. 1999 Jul;11(7):755-9. doi: 10.1097/00042737-199907000-00013.
5
Association of endotoxaemia & gut permeability with complications of acute pancreatitis: Secondary analysis of data.内毒素血症和肠道通透性与急性胰腺炎并发症的关系:数据的二次分析。
Indian J Med Res. 2019 Jun;149(6):763-770. doi: 10.4103/ijmr.IJMR_763_17.
6
The role of the gut barrier function in the pathophysiology of viral liver cirrhosis.肠道屏障功能在病毒性肝硬化病理生理学中的作用。
Hepatogastroenterology. 2011 Jul-Aug;58(109):1244-7. doi: 10.5754/hge10338.
7
Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease.血浆紧密连接蛋白3与肿瘤坏死因子-α诱导的肝病肠源性内毒素血症相关。
Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):410-416. doi: 10.1016/j.clinre.2018.11.014. Epub 2019 Apr 30.
8
Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.利福昔明治疗与肝性脑病患者肝硬化并发症风险降低及总生存期延长相关。
Aliment Pharmacol Ther. 2017 Nov;46(9):845-855. doi: 10.1111/apt.14275. Epub 2017 Aug 24.
9
Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?肝硬化伴自发性细菌性腹膜炎与不伴自发性细菌性腹膜炎患者的肠通透性:环是否闭合?
Am J Gastroenterol. 2010 Feb;105(2):323-7. doi: 10.1038/ajg.2009.558. Epub 2009 Oct 20.
10
Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.利福昔明的长期治疗可改善失代偿性酒精性肝硬化患者的预后。
J Gastroenterol Hepatol. 2013 Mar;28(3):450-5. doi: 10.1111/jgh.12070.

引用本文的文献

1
Gut‑liver axis in liver disease: From basic science to clinical treatment (Review).肠道-肝脏轴在肝脏疾病中的作用:从基础科学到临床治疗(综述)。
Mol Med Rep. 2025 Jan;31(1). doi: 10.3892/mmr.2024.13375. Epub 2024 Oct 25.
2
A retrospective case-series of influence of chronic hepatitis B on synchronous liver metastasis of colorectal cancer.慢性乙型肝炎对结直肠癌同步肝转移影响的回顾性病例系列研究
Front Oncol. 2023 Feb 23;13:1109464. doi: 10.3389/fonc.2023.1109464. eCollection 2023.
3
An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis.
肝硬化患者自发性细菌性腹膜炎全球患病率、耐药性及转归的流行病学荟萃分析
Front Med (Lausanne). 2021 Aug 5;8:693652. doi: 10.3389/fmed.2021.693652. eCollection 2021.
4
Effect of liver transplantation on intestinal permeability and correlation with infection episodes.肝移植对肠道通透性的影响及其与感染发作的相关性。
PLoS One. 2020 Jun 26;15(6):e0235359. doi: 10.1371/journal.pone.0235359. eCollection 2020.
5
Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.肝硬化慢性肝性脑病的饮食方法与肠道微生物群调节
World J Hepatol. 2019 Jun 27;11(6):489-512. doi: 10.4254/wjh.v11.i6.489.
6
Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.终末期肝病和肝移植中细菌和真菌感染的管理:现有选择和未来方向。
World J Gastroenterol. 2018 Oct 14;24(38):4311-4329. doi: 10.3748/wjg.v24.i38.4311.
7
Rifaximin has the potential to prevent complications of cirrhosis.利福昔明有预防肝硬化并发症的潜力。
Therap Adv Gastroenterol. 2018 Sep 28;11:1756284818800307. doi: 10.1177/1756284818800307. eCollection 2018.
8
Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments.牛磺胆酸是一种活性促进因子,而非仅仅是肝硬化进展的生物标志物:来自一项人体代谢组学研究和体外实验的证据。
BMC Gastroenterol. 2018 Jul 11;18(1):112. doi: 10.1186/s12876-018-0842-7.
9
Changes of Intestinal Functions in Liver Cirrhosis.肝硬化患者肠道功能的变化
Inflamm Intest Dis. 2016 Apr;1(1):24-40. doi: 10.1159/000444436. Epub 2016 Mar 8.
10
Amplification of bacterial genomic DNA from all ascitic fluids with a highly sensitive polymerase chain reaction.用高灵敏度聚合酶链反应从所有腹水中扩增细菌基因组 DNA。
Mol Med Rep. 2018 Aug;18(2):2117-2123. doi: 10.3892/mmr.2018.9159. Epub 2018 Jun 14.